[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fVmLr-ejmkyaQ3wN5ilgjCpAYXT3_16InMmKGXu-FrZg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"LG Life Sciences",[4],78,false,0,23,20755,10,[13,16,19,22,25,27,29,31],{"name":14,"count":15},"Healthy",16,{"name":17,"count":18},"Type 2 Diabetes Mellitus",7,{"name":20,"count":21},"Chronic Hepatitis B",3,{"name":23,"count":24},"Infectious Disease by Haemophilus Influenzae Type b",2,{"name":26,"count":24},"Growth Hormone Deficiency",{"name":28,"count":24},"Temporary Correction of Wrinkles",{"name":30,"count":24},"Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)",{"name":32,"count":24},"Hepatitis B",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,79,106,124,149,173,191,219,245,263,287,305,362,408,434,468,490,518,554,588,622,656,680,704,729,747,776,794,812,830,848,866,884,908,926,950,968,996,1014,1032,1050,1068,1086,1120,1148,1182,1204,1226,1250,1273,1291,1309,1335,1353,1403,1429,1465,1487,1509,1531,1553,1575,1598,1616,1640,1663,1686,1704,1727,1745,1767,1785,1803,1827,1850,1874,1898,1916,1934,1952,1973,1991,2013,2036,2054,2078,2101,2125,2143,2166,2220,2245],{"intervention":43,"totalTrials":24,"cells":44},"Sancuso patch",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":77},{"trials":46,"activeCount":8},[],{"trials":48,"activeCount":8},[],{"trials":50,"activeCount":8},[],{"trials":52,"activeCount":8},[],{"trials":54,"activeCount":8},[55,67],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":65},"NCT01662687","Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)","UNKNOWN",[39],"2012-10","2012-11","2012-02",276,[30],[43,66],"Kytril inj.+Kytril tab.",{"nctId":68,"briefTitle":69,"status":70,"phases":71,"primaryCompletion":61,"completion":61,"start":72,"enrollment":73,"conditions":74,"interventions":75},"NCT01659775","Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)","COMPLETED",[39],"2011-08",389,[30],[43,76],"Zofran inj.+Zofran tab.",{"trials":78,"activeCount":8},[],{"intervention":80,"totalTrials":81,"cells":82},"IVF-M HP Inj.",1,{"EARLY_PHASE1":83,"PHASE1":85,"PHASE2":87,"PHASE3":89,"PHASE4":91,"NA":104},{"trials":84,"activeCount":8},[],{"trials":86,"activeCount":8},[],{"trials":88,"activeCount":8},[],{"trials":90,"activeCount":8},[],{"trials":92,"activeCount":8},[93],{"nctId":94,"briefTitle":95,"status":70,"phases":96,"primaryCompletion":97,"start":98,"enrollment":99,"conditions":100,"interventions":102},"NCT02458768","Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.",[39],"2014-11","2013-07",112,[101],"Infertility, Female",[80,103],"Menopur® Inj.",{"trials":105,"activeCount":8},[],{"intervention":103,"totalTrials":81,"cells":107},{"EARLY_PHASE1":108,"PHASE1":110,"PHASE2":112,"PHASE3":114,"PHASE4":116,"NA":122},{"trials":109,"activeCount":8},[],{"trials":111,"activeCount":8},[],{"trials":113,"activeCount":8},[],{"trials":115,"activeCount":8},[],{"trials":117,"activeCount":8},[118],{"nctId":94,"briefTitle":95,"status":70,"phases":119,"primaryCompletion":97,"start":98,"enrollment":99,"conditions":120,"interventions":121},[39],[101],[80,103],{"trials":123,"activeCount":8},[],{"intervention":125,"totalTrials":81,"cells":126},"Ganirelix acetate",{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":135,"NA":147},{"trials":128,"activeCount":8},[],{"trials":130,"activeCount":8},[],{"trials":132,"activeCount":8},[],{"trials":134,"activeCount":8},[],{"trials":136,"activeCount":8},[137],{"nctId":138,"briefTitle":139,"status":70,"phases":140,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":146},"NCT03051087","To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®",[39],"2018-03","2016-10",255,[145],"Controlled Ovarian Stimulation",[125],{"trials":148,"activeCount":8},[],{"intervention":150,"totalTrials":81,"cells":151},"sustained-release recombinant human GH",{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":160,"NA":171},{"trials":153,"activeCount":8},[],{"trials":155,"activeCount":8},[],{"trials":157,"activeCount":8},[],{"trials":159,"activeCount":8},[],{"trials":161,"activeCount":8},[162],{"nctId":163,"briefTitle":164,"status":70,"phases":165,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":170},"NCT01605331","Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)",[39],"2010-09","2009-12",132,[26],[150],{"trials":172,"activeCount":8},[],{"intervention":66,"totalTrials":81,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":189},{"trials":176,"activeCount":8},[],{"trials":178,"activeCount":8},[],{"trials":180,"activeCount":8},[],{"trials":182,"activeCount":8},[],{"trials":184,"activeCount":8},[185],{"nctId":56,"briefTitle":57,"status":58,"phases":186,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":187,"interventions":188},[39],[30],[43,66],{"trials":190,"activeCount":8},[],{"intervention":192,"totalTrials":81,"cells":193},"Somatropin",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":202,"NA":217},{"trials":195,"activeCount":8},[],{"trials":197,"activeCount":8},[],{"trials":199,"activeCount":8},[],{"trials":201,"activeCount":8},[],{"trials":203,"activeCount":8},[204],{"nctId":205,"briefTitle":206,"status":70,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":216},"NCT03015909","Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.",[39],"2017-12-21","2016-08-11",116,[212,213,26,214,215],"Short Stature, Idiopathic","Infant, Small for Gestational Age","Chronic Renal Failure","Turner Syndrome",[192],{"trials":218,"activeCount":8},[],{"intervention":220,"totalTrials":81,"cells":221},"Imidafenacin",{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":243},{"trials":223,"activeCount":8},[],{"trials":225,"activeCount":8},[],{"trials":227,"activeCount":8},[],{"trials":229,"activeCount":8},[],{"trials":231,"activeCount":8},[232],{"nctId":233,"briefTitle":234,"status":70,"phases":235,"primaryCompletion":236,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":241},"NCT01578304","Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder",[39],"2011-10","2010-12",207,[240],"Overactive Bladder",[220,242],"Fesoterodine",{"trials":244,"activeCount":8},[],{"intervention":242,"totalTrials":81,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":261},{"trials":248,"activeCount":8},[],{"trials":250,"activeCount":8},[],{"trials":252,"activeCount":8},[],{"trials":254,"activeCount":8},[],{"trials":256,"activeCount":8},[257],{"nctId":233,"briefTitle":234,"status":70,"phases":258,"primaryCompletion":236,"completion":236,"start":237,"enrollment":238,"conditions":259,"interventions":260},[39],[240],[220,242],{"trials":262,"activeCount":8},[],{"intervention":264,"totalTrials":81,"cells":265},"Gemigliptin + Metformin \u002F Sitagliptin + Metformin \u002F Glimepiride + Metformin",{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":285},{"trials":267,"activeCount":8},[],{"trials":269,"activeCount":8},[],{"trials":271,"activeCount":8},[],{"trials":273,"activeCount":8},[],{"trials":275,"activeCount":8},[276],{"nctId":277,"briefTitle":278,"status":70,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":284},"NCT01890629","Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)",[39],"2014-08","2013-05",69,[17],[264],{"trials":286,"activeCount":8},[],{"intervention":76,"totalTrials":81,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":303},{"trials":290,"activeCount":8},[],{"trials":292,"activeCount":8},[],{"trials":294,"activeCount":8},[],{"trials":296,"activeCount":8},[],{"trials":298,"activeCount":8},[299],{"nctId":68,"briefTitle":69,"status":70,"phases":300,"primaryCompletion":61,"completion":61,"start":72,"enrollment":73,"conditions":301,"interventions":302},[39],[30],[43,76],{"trials":304,"activeCount":8},[],{"intervention":306,"totalTrials":307,"cells":308},"LBEC0101",4,{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":333,"PHASE3":335,"PHASE4":358,"NA":360},{"trials":310,"activeCount":8},[],{"trials":312,"activeCount":8},[313,324],{"nctId":314,"briefTitle":315,"status":70,"phases":316,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":322},"NCT01145950","Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®",[36],"2010-11","2011-01","2010-06",36,[14],[306,323],"Enbrel",{"nctId":325,"briefTitle":326,"status":70,"phases":327,"primaryCompletion":328,"completion":329,"start":61,"enrollment":330,"conditions":331,"interventions":332},"NCT01725620","Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®",[36],"2013-04","2014-04",48,[14],[306,323],{"trials":334,"activeCount":8},[],{"trials":336,"activeCount":8},[337,347],{"nctId":338,"briefTitle":339,"status":58,"phases":340,"primaryCompletion":341,"start":342,"enrollment":343,"conditions":344,"interventions":346},"NCT02357069","A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy",[38],"2016-12","2015-02",372,[345],"Arthritis, Rheumatoid",[323,306],{"nctId":348,"briefTitle":349,"status":70,"phases":350,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":357},"NCT02715908","A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)",[38],"2017-12","2018-04","2016-04",148,[356],"Rheumatoid Arthritis",[306],{"trials":359,"activeCount":8},[],{"trials":361,"activeCount":8},[],{"intervention":363,"totalTrials":21,"cells":364},"Metformin",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":380,"PHASE3":382,"PHASE4":404,"NA":406},{"trials":366,"activeCount":8},[],{"trials":368,"activeCount":8},[369],{"nctId":370,"briefTitle":371,"status":70,"phases":372,"primaryCompletion":373,"completion":374,"start":72,"enrollment":375,"conditions":376,"interventions":377},"NCT01426399","Pharmacokinetic\u002FPharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects",[36],"2011-11","2011-12",30,[14],[378,363,379],"LC15-0444","LC15-0444+Metformin",{"trials":381,"activeCount":8},[],{"trials":383,"activeCount":8},[384,395],{"nctId":385,"briefTitle":386,"status":70,"phases":387,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":392},"NCT02831361","Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)",[38],"2018-02-08","2016-10-17",290,[17],[393,394,363],"Gemigliptin","Gemigliptin placebo",{"nctId":396,"briefTitle":397,"status":70,"phases":398,"primaryCompletion":399,"completion":399,"start":328,"enrollment":400,"conditions":401,"interventions":402},"NCT01787396","Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d",[38],"2015-03",433,[17],[403,363],"Gemigliptin 50mg",{"trials":405,"activeCount":8},[],{"trials":407,"activeCount":8},[],{"intervention":323,"totalTrials":21,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":422,"PHASE3":424,"PHASE4":430,"NA":432},{"trials":411,"activeCount":8},[],{"trials":413,"activeCount":8},[414,418],{"nctId":314,"briefTitle":315,"status":70,"phases":415,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":416,"interventions":417},[36],[14],[306,323],{"nctId":325,"briefTitle":326,"status":70,"phases":419,"primaryCompletion":328,"completion":329,"start":61,"enrollment":330,"conditions":420,"interventions":421},[36],[14],[306,323],{"trials":423,"activeCount":8},[],{"trials":425,"activeCount":8},[426],{"nctId":338,"briefTitle":339,"status":58,"phases":427,"primaryCompletion":341,"start":342,"enrollment":343,"conditions":428,"interventions":429},[38],[345],[323,306],{"trials":431,"activeCount":8},[],{"trials":433,"activeCount":8},[],{"intervention":435,"totalTrials":24,"cells":436},"LBVH0101",{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":464,"NA":466},{"trials":438,"activeCount":8},[],{"trials":440,"activeCount":8},[],{"trials":442,"activeCount":8},[],{"trials":444,"activeCount":8},[445,455],{"nctId":446,"briefTitle":447,"status":70,"phases":448,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":453},"NCT01019772","Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age",[38],"2008-08","2007-07",217,[23],[435,454],"Hiberix™ Vaccine",{"nctId":456,"briefTitle":457,"status":70,"phases":458,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":463},"NCT01251133","Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study",[38],"2009-03","2008-07",122,[23],[435,454],{"trials":465,"activeCount":8},[],{"trials":467,"activeCount":8},[],{"intervention":454,"totalTrials":24,"cells":469},{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":486,"NA":488},{"trials":471,"activeCount":8},[],{"trials":473,"activeCount":8},[],{"trials":475,"activeCount":8},[],{"trials":477,"activeCount":8},[478,482],{"nctId":446,"briefTitle":447,"status":70,"phases":479,"completion":449,"start":450,"enrollment":451,"conditions":480,"interventions":481},[38],[23],[435,454],{"nctId":456,"briefTitle":457,"status":70,"phases":483,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":484,"interventions":485},[38],[23],[435,454],{"trials":487,"activeCount":8},[],{"trials":489,"activeCount":8},[],{"intervention":394,"totalTrials":24,"cells":491},{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":514,"NA":516},{"trials":493,"activeCount":8},[],{"trials":495,"activeCount":8},[],{"trials":497,"activeCount":8},[],{"trials":499,"activeCount":8},[500,504],{"nctId":385,"briefTitle":386,"status":70,"phases":501,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":502,"interventions":503},[38],[17],[393,394,363],{"nctId":505,"briefTitle":506,"status":70,"phases":507,"primaryCompletion":508,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":513},"NCT01990469","Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin",[38],"2015-04","2014-01",219,[512],"T2DM",[393,394],{"trials":515,"activeCount":8},[],{"trials":517,"activeCount":8},[],{"intervention":519,"totalTrials":24,"cells":520},"growth hormone",{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":550,"NA":552},{"trials":522,"activeCount":8},[],{"trials":524,"activeCount":8},[],{"trials":526,"activeCount":8},[],{"trials":528,"activeCount":8},[529,539],{"nctId":530,"briefTitle":531,"status":58,"phases":532,"primaryCompletion":533,"start":534,"enrollment":535,"conditions":536,"interventions":538},"NCT00271518","Treatment of Children With Insufficient Secretion of Growth Hormone",[38],"2013-12","2005-09",144,[537],"Growth Hormone Deficiency (GHD)",[519],{"nctId":540,"briefTitle":541,"status":70,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":549},"NCT00294619","Treatment of Adults With Growth Hormone Deficiency",[38],"2008-03","2006-04",147,[547,548],"Pituitary Disorders","Adult Growth Hormone Deficiency",[519],{"trials":551,"activeCount":8},[],{"trials":553,"activeCount":8},[],{"intervention":555,"totalTrials":24,"cells":556},"LBAL",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":569,"PHASE3":571,"PHASE4":584,"NA":586},{"trials":558,"activeCount":8},[],{"trials":560,"activeCount":8},[561],{"nctId":562,"briefTitle":563,"status":70,"phases":564,"primaryCompletion":342,"completion":342,"start":280,"enrollment":210,"conditions":565,"interventions":567},"NCT02206867","Pharmacokinetics and Safety Study of LBAL in Healthy Subjects",[36],[566],"Healthy Subjects",[555,568],"Humira",{"trials":570,"activeCount":8},[],{"trials":572,"activeCount":8},[573],{"nctId":574,"briefTitle":575,"status":70,"phases":576,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":582},"NCT02746380","A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy",[38],"2017-07-14","2018-02-23","2016-04-13",383,[345],[555,583],"Humira®",{"trials":585,"activeCount":8},[],{"trials":587,"activeCount":8},[],{"intervention":589,"totalTrials":24,"cells":590},"LBSA0103",{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":618,"NA":620},{"trials":592,"activeCount":8},[],{"trials":594,"activeCount":8},[],{"trials":596,"activeCount":8},[],{"trials":598,"activeCount":8},[599,609],{"nctId":600,"briefTitle":601,"status":70,"phases":602,"primaryCompletion":603,"completion":60,"start":374,"enrollment":604,"conditions":605,"interventions":607},"NCT01510535","Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis",[38],"2012-03",287,[606],"Osteoarthritis of the Knee",[608,589],"Hyruan Plus",{"nctId":610,"briefTitle":611,"status":70,"phases":612,"primaryCompletion":613,"completion":613,"start":329,"enrollment":614,"conditions":615,"interventions":617},"NCT02122601","A Clinical Trial to Evaluate the Safety and Efficacy of Retreatment With Intra-articular LBSA0103 Injections in the Patients With Osteoarthritis of the Knee",[38],"2015-05",174,[616],"Osteoarthritis of Knee",[589],{"trials":619,"activeCount":8},[],{"trials":621,"activeCount":8},[],{"intervention":623,"totalTrials":24,"cells":624},"LC15-0444 50mg qd",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":631,"PHASE4":652,"NA":654},{"trials":626,"activeCount":8},[],{"trials":628,"activeCount":8},[],{"trials":630,"activeCount":8},[],{"trials":632,"activeCount":8},[633,644],{"nctId":634,"briefTitle":635,"status":70,"phases":636,"primaryCompletion":637,"completion":638,"start":167,"enrollment":639,"conditions":640,"interventions":641},"NCT01602003","Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes",[38],"2011-06","2012-05",425,[17],[642,623,643],"LC15-0444 25mg bid","Sitagliptin 100mg qd",{"nctId":645,"briefTitle":646,"status":70,"phases":647,"primaryCompletion":648,"completion":373,"start":167,"enrollment":649,"conditions":650,"interventions":651},"NCT01601990","Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes",[38],"2011-03",189,[17],[623],{"trials":653,"activeCount":8},[],{"trials":655,"activeCount":8},[],{"intervention":657,"totalTrials":81,"cells":658},"Eutravac",{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":676,"NA":678},{"trials":660,"activeCount":8},[],{"trials":662,"activeCount":8},[],{"trials":664,"activeCount":8},[],{"trials":666,"activeCount":8},[667],{"nctId":668,"briefTitle":669,"status":70,"phases":670,"primaryCompletion":373,"completion":373,"start":671,"enrollment":672,"conditions":673,"interventions":675},"NCT01896739","A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants",[38],"2009-08",289,[674],"Healthy Infants",[657],{"trials":677,"activeCount":8},[],{"trials":679,"activeCount":8},[],{"intervention":681,"totalTrials":81,"cells":682},"Gemigliptin\u002FGlimepiride combination",{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":700,"NA":702},{"trials":684,"activeCount":8},[],{"trials":686,"activeCount":8},[],{"trials":688,"activeCount":8},[],{"trials":690,"activeCount":8},[691],{"nctId":692,"briefTitle":693,"status":58,"phases":694,"primaryCompletion":695,"start":696,"enrollment":697,"conditions":698,"interventions":699},"NCT02089126","Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes",[38],"2016-09","2014-06",230,[17],[681],{"trials":701,"activeCount":8},[],{"trials":703,"activeCount":8},[],{"intervention":705,"totalTrials":81,"cells":706},"Gemigliptin and\u002For Rosuvastatin",{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":725,"NA":727},{"trials":708,"activeCount":8},[],{"trials":710,"activeCount":8},[],{"trials":712,"activeCount":8},[],{"trials":714,"activeCount":8},[715],{"nctId":716,"briefTitle":717,"status":70,"phases":718,"primaryCompletion":719,"completion":719,"start":720,"enrollment":390,"conditions":721,"interventions":724},"NCT02126358","Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)",[38],"2016-03","2014-05",[722,723],"Type 2 Diabetes","Dyslipidemia",[705],{"trials":726,"activeCount":8},[],{"trials":728,"activeCount":8},[],{"intervention":583,"totalTrials":81,"cells":730},{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":743,"NA":745},{"trials":732,"activeCount":8},[],{"trials":734,"activeCount":8},[],{"trials":736,"activeCount":8},[],{"trials":738,"activeCount":8},[739],{"nctId":574,"briefTitle":575,"status":70,"phases":740,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":741,"interventions":742},[38],[345],[555,583],{"trials":744,"activeCount":8},[],{"trials":746,"activeCount":8},[],{"intervention":748,"totalTrials":81,"cells":749},"Valsartan 160mg",{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":772,"NA":774},{"trials":751,"activeCount":8},[],{"trials":753,"activeCount":8},[],{"trials":755,"activeCount":8},[],{"trials":757,"activeCount":8},[758],{"nctId":759,"briefTitle":760,"status":70,"phases":761,"primaryCompletion":762,"completion":762,"start":763,"enrollment":764,"conditions":765,"interventions":768},"NCT01918332","Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia",[38],"2013-03","2012-04",168,[766,767],"Hypertension,","Hyperlipidemia",[748,769,770,771],"Rosuvastatin 20mg","Valsartan 160mg placebo","Rosuvastatin 20mg placebo",{"trials":773,"activeCount":8},[],{"trials":775,"activeCount":8},[],{"intervention":769,"totalTrials":81,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":790,"NA":792},{"trials":779,"activeCount":8},[],{"trials":781,"activeCount":8},[],{"trials":783,"activeCount":8},[],{"trials":785,"activeCount":8},[786],{"nctId":759,"briefTitle":760,"status":70,"phases":787,"primaryCompletion":762,"completion":762,"start":763,"enrollment":764,"conditions":788,"interventions":789},[38],[766,767],[748,769,770,771],{"trials":791,"activeCount":8},[],{"trials":793,"activeCount":8},[],{"intervention":770,"totalTrials":81,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":808,"NA":810},{"trials":797,"activeCount":8},[],{"trials":799,"activeCount":8},[],{"trials":801,"activeCount":8},[],{"trials":803,"activeCount":8},[804],{"nctId":759,"briefTitle":760,"status":70,"phases":805,"primaryCompletion":762,"completion":762,"start":763,"enrollment":764,"conditions":806,"interventions":807},[38],[766,767],[748,769,770,771],{"trials":809,"activeCount":8},[],{"trials":811,"activeCount":8},[],{"intervention":771,"totalTrials":81,"cells":813},{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":826,"NA":828},{"trials":815,"activeCount":8},[],{"trials":817,"activeCount":8},[],{"trials":819,"activeCount":8},[],{"trials":821,"activeCount":8},[822],{"nctId":759,"briefTitle":760,"status":70,"phases":823,"primaryCompletion":762,"completion":762,"start":763,"enrollment":764,"conditions":824,"interventions":825},[38],[766,767],[748,769,770,771],{"trials":827,"activeCount":8},[],{"trials":829,"activeCount":8},[],{"intervention":608,"totalTrials":81,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":844,"NA":846},{"trials":833,"activeCount":8},[],{"trials":835,"activeCount":8},[],{"trials":837,"activeCount":8},[],{"trials":839,"activeCount":8},[840],{"nctId":600,"briefTitle":601,"status":70,"phases":841,"primaryCompletion":603,"completion":60,"start":374,"enrollment":604,"conditions":842,"interventions":843},[38],[606],[608,589],{"trials":845,"activeCount":8},[],{"trials":847,"activeCount":8},[],{"intervention":642,"totalTrials":81,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":862,"NA":864},{"trials":851,"activeCount":8},[],{"trials":853,"activeCount":8},[],{"trials":855,"activeCount":8},[],{"trials":857,"activeCount":8},[858],{"nctId":634,"briefTitle":635,"status":70,"phases":859,"primaryCompletion":637,"completion":638,"start":167,"enrollment":639,"conditions":860,"interventions":861},[38],[17],[642,623,643],{"trials":863,"activeCount":8},[],{"trials":865,"activeCount":8},[],{"intervention":643,"totalTrials":81,"cells":867},{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":880,"NA":882},{"trials":869,"activeCount":8},[],{"trials":871,"activeCount":8},[],{"trials":873,"activeCount":8},[],{"trials":875,"activeCount":8},[876],{"nctId":634,"briefTitle":635,"status":70,"phases":877,"primaryCompletion":637,"completion":638,"start":167,"enrollment":639,"conditions":878,"interventions":879},[38],[17],[642,623,643],{"trials":881,"activeCount":8},[],{"trials":883,"activeCount":8},[],{"intervention":885,"totalTrials":81,"cells":886},"Eutropin",{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":904,"NA":906},{"trials":888,"activeCount":8},[],{"trials":890,"activeCount":8},[],{"trials":892,"activeCount":8},[],{"trials":894,"activeCount":8},[895],{"nctId":896,"briefTitle":897,"status":70,"phases":898,"primaryCompletion":351,"completion":351,"start":696,"enrollment":899,"conditions":900,"interventions":902},"NCT02204163","Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome",[38],34,[901],"Prader-Willi Syndrome",[885,903],"Genotropin",{"trials":905,"activeCount":8},[],{"trials":907,"activeCount":8},[],{"intervention":903,"totalTrials":81,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":922,"NA":924},{"trials":911,"activeCount":8},[],{"trials":913,"activeCount":8},[],{"trials":915,"activeCount":8},[],{"trials":917,"activeCount":8},[918],{"nctId":896,"briefTitle":897,"status":70,"phases":919,"primaryCompletion":351,"completion":351,"start":696,"enrollment":899,"conditions":920,"interventions":921},[38],[901],[885,903],{"trials":923,"activeCount":8},[],{"trials":925,"activeCount":8},[],{"intervention":927,"totalTrials":81,"cells":928},"Growth hormone - LB03002",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":946,"NA":948},{"trials":930,"activeCount":8},[],{"trials":932,"activeCount":8},[],{"trials":934,"activeCount":8},[],{"trials":936,"activeCount":8},[937],{"nctId":938,"briefTitle":541,"status":70,"phases":939,"primaryCompletion":940,"completion":941,"start":942,"enrollment":943,"conditions":944,"interventions":945},"NCT00596037",[38],"2008-09","2009-05","2006-08",136,[547,548],[927],{"trials":947,"activeCount":8},[],{"trials":949,"activeCount":8},[],{"intervention":403,"totalTrials":81,"cells":951},{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":964,"NA":966},{"trials":953,"activeCount":8},[],{"trials":955,"activeCount":8},[],{"trials":957,"activeCount":8},[],{"trials":959,"activeCount":8},[960],{"nctId":396,"briefTitle":397,"status":70,"phases":961,"primaryCompletion":399,"completion":399,"start":328,"enrollment":400,"conditions":962,"interventions":963},[38],[17],[403,363],{"trials":965,"activeCount":8},[],{"trials":967,"activeCount":8},[],{"intervention":969,"totalTrials":81,"cells":970},"Lercanidipine 10mg",{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":992,"NA":994},{"trials":972,"activeCount":8},[],{"trials":974,"activeCount":8},[],{"trials":976,"activeCount":8},[],{"trials":978,"activeCount":8},[979],{"nctId":980,"briefTitle":981,"status":70,"phases":982,"primaryCompletion":328,"start":638,"enrollment":983,"conditions":984,"interventions":986},"NCT01928628","Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine\u002FValsartan in Hypertensive Patients",[38],449,[985],"Hypertension",[969,987,988,989,990,991],"Lercanidipine10mg \u002FValsartan 80mg","Lercanidipine 10mg \u002FValsartan 160mg","Lercanidipin 10mg Placebo","Lercanidipine10mg \u002FValsartan 80mg Placebo","Lercanidipine 10mg \u002FValsartan 160mg Placebo",{"trials":993,"activeCount":8},[],{"trials":995,"activeCount":8},[],{"intervention":987,"totalTrials":81,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1010,"NA":1012},{"trials":999,"activeCount":8},[],{"trials":1001,"activeCount":8},[],{"trials":1003,"activeCount":8},[],{"trials":1005,"activeCount":8},[1006],{"nctId":980,"briefTitle":981,"status":70,"phases":1007,"primaryCompletion":328,"start":638,"enrollment":983,"conditions":1008,"interventions":1009},[38],[985],[969,987,988,989,990,991],{"trials":1011,"activeCount":8},[],{"trials":1013,"activeCount":8},[],{"intervention":988,"totalTrials":81,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1028,"NA":1030},{"trials":1017,"activeCount":8},[],{"trials":1019,"activeCount":8},[],{"trials":1021,"activeCount":8},[],{"trials":1023,"activeCount":8},[1024],{"nctId":980,"briefTitle":981,"status":70,"phases":1025,"primaryCompletion":328,"start":638,"enrollment":983,"conditions":1026,"interventions":1027},[38],[985],[969,987,988,989,990,991],{"trials":1029,"activeCount":8},[],{"trials":1031,"activeCount":8},[],{"intervention":989,"totalTrials":81,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1046,"NA":1048},{"trials":1035,"activeCount":8},[],{"trials":1037,"activeCount":8},[],{"trials":1039,"activeCount":8},[],{"trials":1041,"activeCount":8},[1042],{"nctId":980,"briefTitle":981,"status":70,"phases":1043,"primaryCompletion":328,"start":638,"enrollment":983,"conditions":1044,"interventions":1045},[38],[985],[969,987,988,989,990,991],{"trials":1047,"activeCount":8},[],{"trials":1049,"activeCount":8},[],{"intervention":990,"totalTrials":81,"cells":1051},{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1058,"PHASE4":1064,"NA":1066},{"trials":1053,"activeCount":8},[],{"trials":1055,"activeCount":8},[],{"trials":1057,"activeCount":8},[],{"trials":1059,"activeCount":8},[1060],{"nctId":980,"briefTitle":981,"status":70,"phases":1061,"primaryCompletion":328,"start":638,"enrollment":983,"conditions":1062,"interventions":1063},[38],[985],[969,987,988,989,990,991],{"trials":1065,"activeCount":8},[],{"trials":1067,"activeCount":8},[],{"intervention":991,"totalTrials":81,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1076,"PHASE4":1082,"NA":1084},{"trials":1071,"activeCount":8},[],{"trials":1073,"activeCount":8},[],{"trials":1075,"activeCount":8},[],{"trials":1077,"activeCount":8},[1078],{"nctId":980,"briefTitle":981,"status":70,"phases":1079,"primaryCompletion":328,"start":638,"enrollment":983,"conditions":1080,"interventions":1081},[38],[985],[969,987,988,989,990,991],{"trials":1083,"activeCount":8},[],{"trials":1085,"activeCount":8},[],{"intervention":1087,"totalTrials":24,"cells":1088},"LB80380",{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1090,"activeCount":8},[],{"trials":1092,"activeCount":8},[],{"trials":1094,"activeCount":8},[1095,1104],{"nctId":1096,"briefTitle":1097,"status":70,"phases":1098,"primaryCompletion":942,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1103},"NCT00895596","Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B",[36,37],"2007-12","2004-03",65,[20],[1087],{"nctId":1105,"briefTitle":1106,"status":58,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1112},"NCT01242787","Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B",[37],"2012-09","2010-08",115,[20],[1087,1113],"Entecavir 0.5 mg",{"trials":1115,"activeCount":8},[],{"trials":1117,"activeCount":8},[],{"trials":1119,"activeCount":8},[],{"intervention":1113,"totalTrials":24,"cells":1121},{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1142,"PHASE4":1144,"NA":1146},{"trials":1123,"activeCount":8},[],{"trials":1125,"activeCount":8},[],{"trials":1127,"activeCount":8},[1128,1132],{"nctId":1105,"briefTitle":1106,"status":58,"phases":1129,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":1130,"interventions":1131},[37],[20],[1087,1113],{"nctId":1133,"briefTitle":1134,"status":70,"phases":1135,"primaryCompletion":317,"completion":1136,"start":671,"enrollment":1110,"conditions":1137,"interventions":1138},"NCT01026610","Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B",[37],"2011-05",[20],[1139,1140,1141],"LB80380 90 mg","LB80380 150 mg","entecavir 0.5 mg",{"trials":1143,"activeCount":8},[],{"trials":1145,"activeCount":8},[],{"trials":1147,"activeCount":8},[],{"intervention":1149,"totalTrials":24,"cells":1150},"LC28-0126 Dose A",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1176,"PHASE4":1178,"NA":1180},{"trials":1152,"activeCount":8},[],{"trials":1154,"activeCount":8},[],{"trials":1156,"activeCount":8},[1157,1168],{"nctId":1158,"briefTitle":1159,"status":70,"phases":1160,"primaryCompletion":1161,"start":509,"enrollment":1162,"conditions":1163,"interventions":1165},"NCT02070471","Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients",[37],"2015-06",60,[1164],"ST-segment Elevation Myocardial Infarction",[1149,1166,1167],"LC28-0126 Dose B","LC28-0126 Dose C",{"nctId":1169,"briefTitle":1170,"status":58,"phases":1171,"primaryCompletion":1172,"start":353,"enrollment":1173,"conditions":1174,"interventions":1175},"NCT02770664","Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients",[37],"2018-08",100,[1164],[1149,1166,1167],{"trials":1177,"activeCount":8},[],{"trials":1179,"activeCount":8},[],{"trials":1181,"activeCount":8},[],{"intervention":1166,"totalTrials":24,"cells":1183},{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1185,"activeCount":8},[],{"trials":1187,"activeCount":8},[],{"trials":1189,"activeCount":8},[1190,1194],{"nctId":1158,"briefTitle":1159,"status":70,"phases":1191,"primaryCompletion":1161,"start":509,"enrollment":1162,"conditions":1192,"interventions":1193},[37],[1164],[1149,1166,1167],{"nctId":1169,"briefTitle":1170,"status":58,"phases":1195,"primaryCompletion":1172,"start":353,"enrollment":1173,"conditions":1196,"interventions":1197},[37],[1164],[1149,1166,1167],{"trials":1199,"activeCount":8},[],{"trials":1201,"activeCount":8},[],{"trials":1203,"activeCount":8},[],{"intervention":1167,"totalTrials":24,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1220,"PHASE4":1222,"NA":1224},{"trials":1207,"activeCount":8},[],{"trials":1209,"activeCount":8},[],{"trials":1211,"activeCount":8},[1212,1216],{"nctId":1158,"briefTitle":1159,"status":70,"phases":1213,"primaryCompletion":1161,"start":509,"enrollment":1162,"conditions":1214,"interventions":1215},[37],[1164],[1149,1166,1167],{"nctId":1169,"briefTitle":1170,"status":58,"phases":1217,"primaryCompletion":1172,"start":353,"enrollment":1173,"conditions":1218,"interventions":1219},[37],[1164],[1149,1166,1167],{"trials":1221,"activeCount":8},[],{"trials":1223,"activeCount":8},[],{"trials":1225,"activeCount":8},[],{"intervention":1227,"totalTrials":81,"cells":1228},"human growth hormone self-injection",{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1230,"activeCount":8},[],{"trials":1232,"activeCount":8},[],{"trials":1234,"activeCount":8},[1235],{"nctId":1236,"briefTitle":1237,"status":70,"phases":1238,"primaryCompletion":399,"completion":399,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1243},"NCT02042170","Efficacy and Safety Study of Sr-hGH in Comparison With Daily hGH in ISS Patients",[37],"2014-02",46,[1242],"Establishing Dose of Sr-hGH in ISS Patients",[1227],{"trials":1245,"activeCount":8},[],{"trials":1247,"activeCount":8},[],{"trials":1249,"activeCount":8},[],{"intervention":1251,"totalTrials":81,"cells":1252},"LD02GIFRO",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1254,"activeCount":8},[],{"trials":1256,"activeCount":8},[],{"trials":1258,"activeCount":8},[1259],{"nctId":1260,"briefTitle":1261,"status":70,"phases":1262,"primaryCompletion":60,"completion":60,"start":603,"enrollment":545,"conditions":1263,"interventions":1266},"NCT01624571","Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO",[37],[1264,1265],"Colon Resection","_large Interstinal Surgery",[1251],{"trials":1268,"activeCount":8},[],{"trials":1270,"activeCount":8},[],{"trials":1272,"activeCount":8},[],{"intervention":1139,"totalTrials":81,"cells":1274},{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1285,"PHASE4":1287,"NA":1289},{"trials":1276,"activeCount":8},[],{"trials":1278,"activeCount":8},[],{"trials":1280,"activeCount":8},[1281],{"nctId":1133,"briefTitle":1134,"status":70,"phases":1282,"primaryCompletion":317,"completion":1136,"start":671,"enrollment":1110,"conditions":1283,"interventions":1284},[37],[20],[1139,1140,1141],{"trials":1286,"activeCount":8},[],{"trials":1288,"activeCount":8},[],{"trials":1290,"activeCount":8},[],{"intervention":1140,"totalTrials":81,"cells":1292},{"EARLY_PHASE1":1293,"PHASE1":1295,"PHASE2":1297,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1294,"activeCount":8},[],{"trials":1296,"activeCount":8},[],{"trials":1298,"activeCount":8},[1299],{"nctId":1133,"briefTitle":1134,"status":70,"phases":1300,"primaryCompletion":317,"completion":1136,"start":671,"enrollment":1110,"conditions":1301,"interventions":1302},[37],[20],[1139,1140,1141],{"trials":1304,"activeCount":8},[],{"trials":1306,"activeCount":8},[],{"trials":1308,"activeCount":8},[],{"intervention":1310,"totalTrials":81,"cells":1311},"Lercanidipine + Valsartan",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1313,"activeCount":8},[],{"trials":1315,"activeCount":8},[],{"trials":1317,"activeCount":8},[1318],{"nctId":1319,"briefTitle":1320,"status":70,"phases":1321,"primaryCompletion":1322,"completion":1323,"start":167,"enrollment":1324,"conditions":1325,"interventions":1327},"NCT01122251","Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension",[37],"2010-05","2010-07",441,[1326],"Essential Hypertension",[1310,1328],"Lercanidipine or Valsartan",{"trials":1330,"activeCount":8},[],{"trials":1332,"activeCount":8},[],{"trials":1334,"activeCount":8},[],{"intervention":1328,"totalTrials":81,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1338,"activeCount":8},[],{"trials":1340,"activeCount":8},[],{"trials":1342,"activeCount":8},[1343],{"nctId":1319,"briefTitle":1320,"status":70,"phases":1344,"primaryCompletion":1322,"completion":1323,"start":167,"enrollment":1324,"conditions":1345,"interventions":1346},[37],[1326],[1310,1328],{"trials":1348,"activeCount":8},[],{"trials":1350,"activeCount":8},[],{"trials":1352,"activeCount":8},[],{"intervention":1354,"totalTrials":307,"cells":1355},"gemigliptin and metformin HCl extended release",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1395,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1357,"activeCount":8},[],{"trials":1359,"activeCount":8},[1360,1368,1377,1386],{"nctId":1361,"briefTitle":1362,"status":70,"phases":1363,"primaryCompletion":61,"completion":762,"start":60,"enrollment":1364,"conditions":1365,"interventions":1366},"NCT01662674","BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone",[36],27,[14],[1354,1367],"gemigliptin\u002Fmetformin HCl extended release",{"nctId":1369,"briefTitle":1370,"status":70,"phases":1371,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1376},"NCT01595880","BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone",[36],"2015-01","2014-12",29,[14],[1354,1367],{"nctId":1378,"briefTitle":1379,"status":70,"phases":1380,"primaryCompletion":329,"completion":720,"start":1381,"enrollment":1382,"conditions":1383,"interventions":1384},"NCT02056600","BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.",[36],"2014-03",24,[14],[1354,1385],"gemigliptin\u002Fmetformin HCl sustained release",{"nctId":1387,"briefTitle":1388,"status":58,"phases":1389,"primaryCompletion":1390,"completion":719,"start":1391,"enrollment":1392,"conditions":1393,"interventions":1394},"NCT02670018","BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone",[36],"2015-12","2015-08",25,[14],[1354,1367],{"trials":1396,"activeCount":8},[],{"trials":1398,"activeCount":8},[],{"trials":1400,"activeCount":8},[],{"trials":1402,"activeCount":8},[],{"intervention":1367,"totalTrials":21,"cells":1404},{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1421,"PHASE3":1423,"PHASE4":1425,"NA":1427},{"trials":1406,"activeCount":8},[],{"trials":1408,"activeCount":8},[1409,1413,1417],{"nctId":1361,"briefTitle":1362,"status":70,"phases":1410,"primaryCompletion":61,"completion":762,"start":60,"enrollment":1364,"conditions":1411,"interventions":1412},[36],[14],[1354,1367],{"nctId":1369,"briefTitle":1370,"status":70,"phases":1414,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1415,"interventions":1416},[36],[14],[1354,1367],{"nctId":1387,"briefTitle":1388,"status":58,"phases":1418,"primaryCompletion":1390,"completion":719,"start":1391,"enrollment":1392,"conditions":1419,"interventions":1420},[36],[14],[1354,1367],{"trials":1422,"activeCount":8},[],{"trials":1424,"activeCount":8},[],{"trials":1426,"activeCount":8},[],{"trials":1428,"activeCount":8},[],{"intervention":1430,"totalTrials":24,"cells":1431},"Sequence 1 : Period 1",{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1457,"PHASE3":1459,"PHASE4":1461,"NA":1463},{"trials":1433,"activeCount":8},[],{"trials":1435,"activeCount":8},[1436,1449],{"nctId":1437,"briefTitle":1438,"status":70,"phases":1439,"primaryCompletion":373,"completion":373,"start":1440,"enrollment":375,"conditions":1441,"interventions":1443},"NCT01918709","Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers",[36],"2011-09",[1442],"Hypertension, Hyperlipidemia",[1430,1444,1445,1446,1447,1448],"Sequence 2 : Period 1","Sequence 3 : Period 1","Sequence 4 : Period 1","Sequence 5 : Period 1","Sequence 6 : Period 1",{"nctId":1450,"briefTitle":1451,"status":70,"phases":1452,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":1162,"conditions":1455,"interventions":1456},"NCT01918358","Safety and Pharmacokinetics Between Fixed-dose Combination VR 160\u002F20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg",[36],"2013-01","2012-12",[985,767],[1430,1444,1445,1446,1447,1448],{"trials":1458,"activeCount":8},[],{"trials":1460,"activeCount":8},[],{"trials":1462,"activeCount":8},[],{"trials":1464,"activeCount":8},[],{"intervention":1444,"totalTrials":24,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1479,"PHASE3":1481,"PHASE4":1483,"NA":1485},{"trials":1468,"activeCount":8},[],{"trials":1470,"activeCount":8},[1471,1475],{"nctId":1437,"briefTitle":1438,"status":70,"phases":1472,"primaryCompletion":373,"completion":373,"start":1440,"enrollment":375,"conditions":1473,"interventions":1474},[36],[1442],[1430,1444,1445,1446,1447,1448],{"nctId":1450,"briefTitle":1451,"status":70,"phases":1476,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":1162,"conditions":1477,"interventions":1478},[36],[985,767],[1430,1444,1445,1446,1447,1448],{"trials":1480,"activeCount":8},[],{"trials":1482,"activeCount":8},[],{"trials":1484,"activeCount":8},[],{"trials":1486,"activeCount":8},[],{"intervention":1445,"totalTrials":24,"cells":1488},{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1501,"PHASE3":1503,"PHASE4":1505,"NA":1507},{"trials":1490,"activeCount":8},[],{"trials":1492,"activeCount":8},[1493,1497],{"nctId":1437,"briefTitle":1438,"status":70,"phases":1494,"primaryCompletion":373,"completion":373,"start":1440,"enrollment":375,"conditions":1495,"interventions":1496},[36],[1442],[1430,1444,1445,1446,1447,1448],{"nctId":1450,"briefTitle":1451,"status":70,"phases":1498,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":1162,"conditions":1499,"interventions":1500},[36],[985,767],[1430,1444,1445,1446,1447,1448],{"trials":1502,"activeCount":8},[],{"trials":1504,"activeCount":8},[],{"trials":1506,"activeCount":8},[],{"trials":1508,"activeCount":8},[],{"intervention":1446,"totalTrials":24,"cells":1510},{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1523,"PHASE3":1525,"PHASE4":1527,"NA":1529},{"trials":1512,"activeCount":8},[],{"trials":1514,"activeCount":8},[1515,1519],{"nctId":1437,"briefTitle":1438,"status":70,"phases":1516,"primaryCompletion":373,"completion":373,"start":1440,"enrollment":375,"conditions":1517,"interventions":1518},[36],[1442],[1430,1444,1445,1446,1447,1448],{"nctId":1450,"briefTitle":1451,"status":70,"phases":1520,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":1162,"conditions":1521,"interventions":1522},[36],[985,767],[1430,1444,1445,1446,1447,1448],{"trials":1524,"activeCount":8},[],{"trials":1526,"activeCount":8},[],{"trials":1528,"activeCount":8},[],{"trials":1530,"activeCount":8},[],{"intervention":1447,"totalTrials":24,"cells":1532},{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1545,"PHASE3":1547,"PHASE4":1549,"NA":1551},{"trials":1534,"activeCount":8},[],{"trials":1536,"activeCount":8},[1537,1541],{"nctId":1437,"briefTitle":1438,"status":70,"phases":1538,"primaryCompletion":373,"completion":373,"start":1440,"enrollment":375,"conditions":1539,"interventions":1540},[36],[1442],[1430,1444,1445,1446,1447,1448],{"nctId":1450,"briefTitle":1451,"status":70,"phases":1542,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":1162,"conditions":1543,"interventions":1544},[36],[985,767],[1430,1444,1445,1446,1447,1448],{"trials":1546,"activeCount":8},[],{"trials":1548,"activeCount":8},[],{"trials":1550,"activeCount":8},[],{"trials":1552,"activeCount":8},[],{"intervention":1448,"totalTrials":24,"cells":1554},{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1567,"PHASE3":1569,"PHASE4":1571,"NA":1573},{"trials":1556,"activeCount":8},[],{"trials":1558,"activeCount":8},[1559,1563],{"nctId":1437,"briefTitle":1438,"status":70,"phases":1560,"primaryCompletion":373,"completion":373,"start":1440,"enrollment":375,"conditions":1561,"interventions":1562},[36],[1442],[1430,1444,1445,1446,1447,1448],{"nctId":1450,"briefTitle":1451,"status":70,"phases":1564,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":1162,"conditions":1565,"interventions":1566},[36],[985,767],[1430,1444,1445,1446,1447,1448],{"trials":1568,"activeCount":8},[],{"trials":1570,"activeCount":8},[],{"trials":1572,"activeCount":8},[],{"trials":1574,"activeCount":8},[],{"intervention":1576,"totalTrials":81,"cells":1577},"Gemigliptin and Glimepiride",{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1590,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1579,"activeCount":8},[],{"trials":1581,"activeCount":8},[1582],{"nctId":1583,"briefTitle":1584,"status":70,"phases":1585,"primaryCompletion":328,"start":1586,"enrollment":1364,"conditions":1587,"interventions":1588},"NCT01768455","Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects",[36],"2013-02",[14],[1576,1589],"Glimepiride",{"trials":1591,"activeCount":8},[],{"trials":1593,"activeCount":8},[],{"trials":1595,"activeCount":8},[],{"trials":1597,"activeCount":8},[],{"intervention":1589,"totalTrials":81,"cells":1599},{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1608,"PHASE3":1610,"PHASE4":1612,"NA":1614},{"trials":1601,"activeCount":8},[],{"trials":1603,"activeCount":8},[1604],{"nctId":1583,"briefTitle":1584,"status":70,"phases":1605,"primaryCompletion":328,"start":1586,"enrollment":1364,"conditions":1606,"interventions":1607},[36],[14],[1576,1589],{"trials":1609,"activeCount":8},[],{"trials":1611,"activeCount":8},[],{"trials":1613,"activeCount":8},[],{"trials":1615,"activeCount":8},[],{"intervention":1617,"totalTrials":81,"cells":1618},"Factive® Tab \u002F Factive IV",{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1632,"PHASE3":1634,"PHASE4":1636,"NA":1638},{"trials":1620,"activeCount":8},[],{"trials":1622,"activeCount":8},[1623],{"nctId":1624,"briefTitle":1625,"status":70,"phases":1626,"primaryCompletion":1627,"start":1628,"enrollment":15,"conditions":1629,"interventions":1631},"NCT01879007","Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)",[36],"2006-03","2006-01",[1630],"Infectious Diseases",[1617],{"trials":1633,"activeCount":8},[],{"trials":1635,"activeCount":8},[],{"trials":1637,"activeCount":8},[],{"trials":1639,"activeCount":8},[],{"intervention":1641,"totalTrials":81,"cells":1642},"LC28-0126",{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1655,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1644,"activeCount":8},[],{"trials":1646,"activeCount":8},[1647],{"nctId":1648,"briefTitle":1649,"status":70,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1454,"enrollment":1652,"conditions":1653,"interventions":1654},"NCT01737424","Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects",[36],"2013-09",89,[14],[1641],{"trials":1656,"activeCount":8},[],{"trials":1658,"activeCount":8},[],{"trials":1660,"activeCount":8},[],{"trials":1662,"activeCount":8},[],{"intervention":1664,"totalTrials":81,"cells":1665},"BEPO-A",{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1678,"PHASE3":1680,"PHASE4":1682,"NA":1684},{"trials":1667,"activeCount":8},[],{"trials":1669,"activeCount":8},[1670],{"nctId":1671,"briefTitle":1672,"status":70,"phases":1673,"primaryCompletion":613,"completion":1674,"start":508,"enrollment":1240,"conditions":1675,"interventions":1676},"NCT02426151","Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects",[36],"2015-09",[14],[1664,1677],"REPO-A",{"trials":1679,"activeCount":8},[],{"trials":1681,"activeCount":8},[],{"trials":1683,"activeCount":8},[],{"trials":1685,"activeCount":8},[],{"intervention":1677,"totalTrials":81,"cells":1687},{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1696,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1689,"activeCount":8},[],{"trials":1691,"activeCount":8},[1692],{"nctId":1671,"briefTitle":1672,"status":70,"phases":1693,"primaryCompletion":613,"completion":1674,"start":508,"enrollment":1240,"conditions":1694,"interventions":1695},[36],[14],[1664,1677],{"trials":1697,"activeCount":8},[],{"trials":1699,"activeCount":8},[],{"trials":1701,"activeCount":8},[],{"trials":1703,"activeCount":8},[],{"intervention":1705,"totalTrials":81,"cells":1706},"Ketoconazole",{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1719,"PHASE3":1721,"PHASE4":1723,"NA":1725},{"trials":1708,"activeCount":8},[],{"trials":1710,"activeCount":8},[1711],{"nctId":1712,"briefTitle":1713,"status":70,"phases":1714,"primaryCompletion":648,"completion":648,"start":318,"enrollment":1382,"conditions":1715,"interventions":1717},"NCT01426906","Pharmacokinetic Drug Interaction Study in Healthy Male Subjects",[36],[1716],"Healthy Male Volunteers",[1705,1718],"rifampicin",{"trials":1720,"activeCount":8},[],{"trials":1722,"activeCount":8},[],{"trials":1724,"activeCount":8},[],{"trials":1726,"activeCount":8},[],{"intervention":1718,"totalTrials":81,"cells":1728},{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1737,"PHASE3":1739,"PHASE4":1741,"NA":1743},{"trials":1730,"activeCount":8},[],{"trials":1732,"activeCount":8},[1733],{"nctId":1712,"briefTitle":1713,"status":70,"phases":1734,"primaryCompletion":648,"completion":648,"start":318,"enrollment":1382,"conditions":1735,"interventions":1736},[36],[1716],[1705,1718],{"trials":1738,"activeCount":8},[],{"trials":1740,"activeCount":8},[],{"trials":1742,"activeCount":8},[],{"trials":1744,"activeCount":8},[],{"intervention":1746,"totalTrials":81,"cells":1747},"Apetrol ES",{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1759,"PHASE3":1761,"PHASE4":1763,"NA":1765},{"trials":1749,"activeCount":8},[],{"trials":1751,"activeCount":8},[1752],{"nctId":1753,"briefTitle":1754,"status":70,"phases":1755,"primaryCompletion":1136,"completion":72,"start":648,"enrollment":1756,"conditions":1757,"interventions":1758},"NCT01342055","Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male Volunteers",[36],38,[1716],[1746],{"trials":1760,"activeCount":8},[],{"trials":1762,"activeCount":8},[],{"trials":1764,"activeCount":8},[],{"trials":1766,"activeCount":8},[],{"intervention":378,"totalTrials":81,"cells":1768},{"EARLY_PHASE1":1769,"PHASE1":1771,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1783},{"trials":1770,"activeCount":8},[],{"trials":1772,"activeCount":8},[1773],{"nctId":370,"briefTitle":371,"status":70,"phases":1774,"primaryCompletion":373,"completion":374,"start":72,"enrollment":375,"conditions":1775,"interventions":1776},[36],[14],[378,363,379],{"trials":1778,"activeCount":8},[],{"trials":1780,"activeCount":8},[],{"trials":1782,"activeCount":8},[],{"trials":1784,"activeCount":8},[],{"intervention":379,"totalTrials":81,"cells":1786},{"EARLY_PHASE1":1787,"PHASE1":1789,"PHASE2":1795,"PHASE3":1797,"PHASE4":1799,"NA":1801},{"trials":1788,"activeCount":8},[],{"trials":1790,"activeCount":8},[1791],{"nctId":370,"briefTitle":371,"status":70,"phases":1792,"primaryCompletion":373,"completion":374,"start":72,"enrollment":375,"conditions":1793,"interventions":1794},[36],[14],[378,363,379],{"trials":1796,"activeCount":8},[],{"trials":1798,"activeCount":8},[],{"trials":1800,"activeCount":8},[],{"trials":1802,"activeCount":8},[],{"intervention":1804,"totalTrials":81,"cells":1805},"LC350189",{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1819,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1807,"activeCount":8},[],{"trials":1809,"activeCount":8},[1810],{"nctId":1811,"briefTitle":1812,"status":70,"phases":1813,"primaryCompletion":1453,"completion":1453,"start":637,"enrollment":1814,"conditions":1815,"interventions":1818},"NCT01361646","Safety, Tolerability and Pharmacokinetic\u002FPharmacodynamic Characteristics of LC350189",[36],129,[1816,1817],"Hyperuricemia","Gout",[1804],{"trials":1820,"activeCount":8},[],{"trials":1822,"activeCount":8},[],{"trials":1824,"activeCount":8},[],{"trials":1826,"activeCount":8},[],{"intervention":1828,"totalTrials":81,"cells":1829},"gemigliptin 50mg, rosuvastatin 20mg",{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1842,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1831,"activeCount":8},[],{"trials":1833,"activeCount":8},[1834],{"nctId":1835,"briefTitle":1836,"status":58,"phases":1837,"primaryCompletion":353,"completion":1838,"start":719,"enrollment":1839,"conditions":1840,"interventions":1841},"NCT02670070","BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone",[36],"2016-06",37,[14],[1828],{"trials":1843,"activeCount":8},[],{"trials":1845,"activeCount":8},[],{"trials":1847,"activeCount":8},[],{"trials":1849,"activeCount":8},[],{"intervention":1851,"totalTrials":81,"cells":1852},"Apetrol ES \u002F Megace",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1866,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1854,"activeCount":8},[],{"trials":1856,"activeCount":8},[1857],{"nctId":1858,"briefTitle":1859,"status":70,"phases":1860,"primaryCompletion":319,"completion":1861,"start":1862,"enrollment":1863,"conditions":1864,"interventions":1865},"NCT02446353","Pharmacokinetics and Safety Study of Apetrol ES",[36],"2010-10","2010-04",79,[14],[1851],{"trials":1867,"activeCount":8},[],{"trials":1869,"activeCount":8},[],{"trials":1871,"activeCount":8},[],{"trials":1873,"activeCount":8},[],{"intervention":1875,"totalTrials":81,"cells":1876},"gemigliptin only",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1890,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1878,"activeCount":8},[],{"trials":1880,"activeCount":8},[1881],{"nctId":1882,"briefTitle":1883,"status":70,"phases":1884,"primaryCompletion":281,"completion":1885,"start":328,"enrollment":375,"conditions":1886,"interventions":1887},"NCT01823133","Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin",[36],"2013-08",[14],[1875,1888,1889],"rosuvastatin only","gemigliptin and rosuvastatin",{"trials":1891,"activeCount":8},[],{"trials":1893,"activeCount":8},[],{"trials":1895,"activeCount":8},[],{"trials":1897,"activeCount":8},[],{"intervention":1888,"totalTrials":81,"cells":1899},{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1908,"PHASE3":1910,"PHASE4":1912,"NA":1914},{"trials":1901,"activeCount":8},[],{"trials":1903,"activeCount":8},[1904],{"nctId":1882,"briefTitle":1883,"status":70,"phases":1905,"primaryCompletion":281,"completion":1885,"start":328,"enrollment":375,"conditions":1906,"interventions":1907},[36],[14],[1875,1888,1889],{"trials":1909,"activeCount":8},[],{"trials":1911,"activeCount":8},[],{"trials":1913,"activeCount":8},[],{"trials":1915,"activeCount":8},[],{"intervention":1889,"totalTrials":81,"cells":1917},{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1926,"PHASE3":1928,"PHASE4":1930,"NA":1932},{"trials":1919,"activeCount":8},[],{"trials":1921,"activeCount":8},[1922],{"nctId":1882,"briefTitle":1883,"status":70,"phases":1923,"primaryCompletion":281,"completion":1885,"start":328,"enrollment":375,"conditions":1924,"interventions":1925},[36],[14],[1875,1888,1889],{"trials":1927,"activeCount":8},[],{"trials":1929,"activeCount":8},[],{"trials":1931,"activeCount":8},[],{"trials":1933,"activeCount":8},[],{"intervention":568,"totalTrials":81,"cells":1935},{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1944,"PHASE3":1946,"PHASE4":1948,"NA":1950},{"trials":1937,"activeCount":8},[],{"trials":1939,"activeCount":8},[1940],{"nctId":562,"briefTitle":563,"status":70,"phases":1941,"primaryCompletion":342,"completion":342,"start":280,"enrollment":210,"conditions":1942,"interventions":1943},[36],[566],[555,568],{"trials":1945,"activeCount":8},[],{"trials":1947,"activeCount":8},[],{"trials":1949,"activeCount":8},[],{"trials":1951,"activeCount":8},[],{"intervention":1953,"totalTrials":81,"cells":1954},"FDC",{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1965,"PHASE3":1967,"PHASE4":1969,"NA":1971},{"trials":1956,"activeCount":8},[],{"trials":1958,"activeCount":8},[1959],{"nctId":1960,"briefTitle":1961,"status":70,"phases":1962,"primaryCompletion":762,"completion":328,"start":1453,"enrollment":1382,"conditions":1963,"interventions":1964},"NCT01747083","Food-Effect Bioavailability Study of FDC(Gemigliptin\u002FMetformin HCl Sustained Release) 50\u002F1000mg(25\u002F500mg x 2tablets)",[36],[722],[1953],{"trials":1966,"activeCount":8},[],{"trials":1968,"activeCount":8},[],{"trials":1970,"activeCount":8},[],{"trials":1972,"activeCount":8},[],{"intervention":1385,"totalTrials":81,"cells":1974},{"EARLY_PHASE1":1975,"PHASE1":1977,"PHASE2":1983,"PHASE3":1985,"PHASE4":1987,"NA":1989},{"trials":1976,"activeCount":8},[],{"trials":1978,"activeCount":8},[1979],{"nctId":1378,"briefTitle":1379,"status":70,"phases":1980,"primaryCompletion":329,"completion":720,"start":1381,"enrollment":1382,"conditions":1981,"interventions":1982},[36],[14],[1354,1385],{"trials":1984,"activeCount":8},[],{"trials":1986,"activeCount":8},[],{"trials":1988,"activeCount":8},[],{"trials":1990,"activeCount":8},[],{"intervention":1992,"totalTrials":81,"cells":1993},"Irbesartan",{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":2005,"PHASE3":2007,"PHASE4":2009,"NA":2011},{"trials":1995,"activeCount":8},[],{"trials":1997,"activeCount":8},[1998],{"nctId":1999,"briefTitle":2000,"status":70,"phases":2001,"primaryCompletion":1651,"completion":1381,"start":2002,"enrollment":375,"conditions":2003,"interventions":2004},"NCT01825850","Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects",[36],"2013-06",[14],[393,1992],{"trials":2006,"activeCount":8},[],{"trials":2008,"activeCount":8},[],{"trials":2010,"activeCount":8},[],{"trials":2012,"activeCount":8},[],{"intervention":2014,"totalTrials":81,"cells":2015},"LB80380 maleate salt",{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2028,"PHASE3":2030,"PHASE4":2032,"NA":2034},{"trials":2017,"activeCount":8},[],{"trials":2019,"activeCount":8},[2020],{"nctId":2021,"briefTitle":2022,"status":70,"phases":2023,"primaryCompletion":317,"completion":237,"start":166,"enrollment":2024,"conditions":2025,"interventions":2026},"NCT01427868","Bioequivalence of LB80380 Free Base and Maleate Salt Tablets",[36],32,[32],[2014,2027],"LB80380 free base",{"trials":2029,"activeCount":8},[],{"trials":2031,"activeCount":8},[],{"trials":2033,"activeCount":8},[],{"trials":2035,"activeCount":8},[],{"intervention":2027,"totalTrials":81,"cells":2037},{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2046,"PHASE3":2048,"PHASE4":2050,"NA":2052},{"trials":2039,"activeCount":8},[],{"trials":2041,"activeCount":8},[2042],{"nctId":2021,"briefTitle":2022,"status":70,"phases":2043,"primaryCompletion":317,"completion":237,"start":166,"enrollment":2024,"conditions":2044,"interventions":2045},[36],[32],[2014,2027],{"trials":2047,"activeCount":8},[],{"trials":2049,"activeCount":8},[],{"trials":2051,"activeCount":8},[],{"trials":2053,"activeCount":8},[],{"intervention":2055,"totalTrials":81,"cells":2056},"Pneumococcal conjugate vaccine",{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2070,"PHASE3":2072,"PHASE4":2074,"NA":2076},{"trials":2058,"activeCount":8},[],{"trials":2060,"activeCount":8},[2061],{"nctId":2062,"briefTitle":2063,"status":70,"phases":2064,"primaryCompletion":2065,"completion":2065,"start":695,"enrollment":2066,"conditions":2067,"interventions":2069},"NCT02892812","A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults",[36],"2016-11",63,[2068],"Pneumococcal Infections",[2055],{"trials":2071,"activeCount":8},[],{"trials":2073,"activeCount":8},[],{"trials":2075,"activeCount":8},[],{"trials":2077,"activeCount":8},[],{"intervention":2079,"totalTrials":81,"cells":2080},"[14C]-LC15-0444",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2093,"PHASE3":2095,"PHASE4":2097,"NA":2099},{"trials":2082,"activeCount":8},[],{"trials":2084,"activeCount":8},[2085],{"nctId":2086,"briefTitle":2087,"status":70,"phases":2088,"primaryCompletion":1136,"completion":2089,"start":1136,"enrollment":2090,"conditions":2091,"interventions":2092},"NCT01603238","Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444",[36],"2011-07",6,[14],[2079],{"trials":2094,"activeCount":8},[],{"trials":2096,"activeCount":8},[],{"trials":2098,"activeCount":8},[],{"trials":2100,"activeCount":8},[],{"intervention":2102,"totalTrials":81,"cells":2103},"LC23-1306",{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2117,"PHASE3":2119,"PHASE4":2121,"NA":2123},{"trials":2105,"activeCount":8},[],{"trials":2107,"activeCount":8},[2108],{"nctId":2109,"briefTitle":2110,"status":70,"phases":2111,"primaryCompletion":61,"completion":1885,"start":603,"enrollment":2112,"conditions":2113,"interventions":2115},"NCT01526577","Study of LC23-1306 in Healthy Male Subjects",[36],113,[2114],"Acute Coronary Syndrome",[2102,2116],"Ticagrelor",{"trials":2118,"activeCount":8},[],{"trials":2120,"activeCount":8},[],{"trials":2122,"activeCount":8},[],{"trials":2124,"activeCount":8},[],{"intervention":2116,"totalTrials":81,"cells":2126},{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2135,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2128,"activeCount":8},[],{"trials":2130,"activeCount":8},[2131],{"nctId":2109,"briefTitle":2110,"status":70,"phases":2132,"primaryCompletion":61,"completion":1885,"start":603,"enrollment":2112,"conditions":2133,"interventions":2134},[36],[2114],[2102,2116],{"trials":2136,"activeCount":8},[],{"trials":2138,"activeCount":8},[],{"trials":2140,"activeCount":8},[],{"trials":2142,"activeCount":8},[],{"intervention":2144,"totalTrials":81,"cells":2145},"LC15-0444, Pioglitazone",{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2158,"PHASE3":2160,"PHASE4":2162,"NA":2164},{"trials":2147,"activeCount":8},[],{"trials":2149,"activeCount":8},[2150],{"nctId":2151,"briefTitle":2152,"status":70,"phases":2153,"primaryCompletion":2154,"completion":167,"start":2155,"enrollment":1382,"conditions":2156,"interventions":2157},"NCT01001013","Pharmacokinetic Drug Interaction Between LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects",[36],"2009-06","2009-02",[14],[2144],{"trials":2159,"activeCount":8},[],{"trials":2161,"activeCount":8},[],{"trials":2163,"activeCount":8},[],{"trials":2165,"activeCount":8},[],{"intervention":393,"totalTrials":2090,"cells":2167},{"EARLY_PHASE1":2168,"PHASE1":2170,"PHASE2":2185,"PHASE3":2187,"PHASE4":2206,"NA":2208},{"trials":2169,"activeCount":8},[],{"trials":2171,"activeCount":8},[2172,2181],{"nctId":2173,"briefTitle":2174,"status":70,"phases":2175,"primaryCompletion":720,"completion":2176,"start":1651,"enrollment":2177,"conditions":2178,"interventions":2180},"NCT02004587","Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers",[36],"2014-07",28,[2179],"Hepatic Impairment",[393],{"nctId":1999,"briefTitle":2000,"status":70,"phases":2182,"primaryCompletion":1651,"completion":1381,"start":2002,"enrollment":375,"conditions":2183,"interventions":2184},[36],[14],[393,1992],{"trials":2186,"activeCount":8},[],{"trials":2188,"activeCount":8},[2189,2193,2202],{"nctId":385,"briefTitle":386,"status":70,"phases":2190,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":2191,"interventions":2192},[38],[17],[393,394,363],{"nctId":2194,"briefTitle":2195,"status":70,"phases":2196,"primaryCompletion":2197,"completion":2197,"start":2198,"enrollment":168,"conditions":2199,"interventions":2201},"NCT01968044","A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)",[38],"2015-10","2013-10",[2200],"Type 2 DM Patients With Moderate or Severe Renal Impairment",[393],{"nctId":505,"briefTitle":506,"status":70,"phases":2203,"primaryCompletion":508,"completion":508,"start":509,"enrollment":510,"conditions":2204,"interventions":2205},[38],[512],[393,394],{"trials":2207,"activeCount":8},[],{"trials":2209,"activeCount":8},[2210],{"nctId":2211,"briefTitle":2212,"status":70,"phases":2213,"primaryCompletion":2214,"completion":2214,"start":2215,"enrollment":2216,"conditions":2217,"interventions":2218},"NCT02290301","An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin",[],"2017-11-30","2013-06-28",5180,[17],[2219],"gemigliptin",{"intervention":2221,"totalTrials":81,"cells":2222},"Levacalm",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2229,"PHASE4":2231,"NA":2233},{"trials":2224,"activeCount":8},[],{"trials":2226,"activeCount":8},[],{"trials":2228,"activeCount":8},[],{"trials":2230,"activeCount":8},[],{"trials":2232,"activeCount":8},[],{"trials":2234,"activeCount":8},[2235],{"nctId":2236,"briefTitle":2237,"status":58,"phases":2238,"primaryCompletion":142,"completion":2065,"start":2176,"enrollment":2239,"conditions":2240,"interventions":2243},"NCT02415192","Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan\u002FAmlodipine Combination Therapy in Essential Hypertension Patients",[],2001,[2241,2242],"Lower Leg Edema","Orthostatic Hypertension",[2221,2244],"Valsartan\u002Famlodipine",{"intervention":2244,"totalTrials":81,"cells":2246},{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2253,"PHASE4":2255,"NA":2257},{"trials":2248,"activeCount":8},[],{"trials":2250,"activeCount":8},[],{"trials":2252,"activeCount":8},[],{"trials":2254,"activeCount":8},[],{"trials":2256,"activeCount":8},[],{"trials":2258,"activeCount":8},[2259],{"nctId":2236,"briefTitle":2237,"status":58,"phases":2260,"primaryCompletion":142,"completion":2065,"start":2176,"enrollment":2239,"conditions":2261,"interventions":2262},[],[2241,2242],[2221,2244]]